Lars Fruergaard Jørgensen, Novo Nordisk CEO (Photographer: Christopher Goodney/Bloomberg via Getty Images)

No­vo Nordisk to re­strict starter dose sup­ply for weight loss drug We­govy

Faced with “all-time high lev­els” of new pa­tients start­ing No­vo Nordisk’s GLP-1 prod­ucts, the com­pa­ny is tem­porar­i­ly re­strict­ing its sup­ply of low­er We­govy dose strengths to “safe­guard con­ti­nu­ity of care,” ac­cord­ing to EVP of North Amer­i­ca op­er­a­tions Doug Lan­ga.

The com­pa­ny will on­ly be able to sup­ply a lim­it­ed amount of 0.25 mg, 0.5 mg and 1 mg dos­es to whole­salers for dis­tri­b­u­tion to re­tail phar­ma­cies which “will not meet an­tic­i­pat­ed pa­tient de­mand,” a spokesper­son told End­points News. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.